Talk Bio

Incyte's oral JAK inhibitor povorcitinib achieved primary endpoints in two Phase 3 trials (STOP-V1 and STOP-V2) for nonsegmental vitiligo in adults 1 Both trials met the primary endpoint of more than 75% reduction in facial vitiligo score at week 52, with 18.9% of povorcitinib-treated patients reaching this threshold compared to 6.8% and 3.1% in the respective control groups 1 The 30 mg dose of povorcitinib demonstrated statistically significant and clinically meaningful improvements in secondary endpoints, including 50% or greater reduction in body vitiligo 1 Povorcitinib did not achieve results comparable to AbbVie's Rinvoq, indicating competitive positioning in the vitiligo treatment market 1 The company plans to file for regulatory approval based on these Phase 3 results 1 Sources: 1. https://www.fiercebiotech.com/biotech/incytes-jak-inhibitor-scores-phase-3-vitiligo-wins-cant-quite-shake-rinvoq